Anne Marie Barnett, MD
Endocrinology · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 10 years
- Graduated 2016
Offices
1 location · Dignity Health Medical Foundation · 1,211 clinicians in this group
Looking this up.
Hospitals listed: Mark Twain Medical Center · St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Barnett’s office at (209) 546-5200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A188756 · Current
Licensed to practise in California · since 2023 · expires 2027-08-31 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mark Twain Medical CenterSan Andreas, CACritical Access Hospital · Voluntary non-profit - Other · No emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for Mark Twain Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 9.3 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.9 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 353 cases | None | Jul 2024 – Jun 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 81.9 · 54 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33.7 · 108 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4 to 9.3) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (7.3 to 14.2) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.4) · 375 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 89 cases | No different | Jan 2024 – Dec 2024 |
What patients said (151 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 89% |
| Nurses "always" communicated well | 90% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 85% |
| Nurses "always" listened carefully | 91% |
| Nurses "always" treated them with courtesy and respect | 93% |
| "Always" quiet at night | 65% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 60% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$40,526
Medicare paid this office $40,526 for 123 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 80 | $14,134 | $94 |
| Long return visit (40+ min) | 41 | $10,067 | $140 |
| New patient visit (60+ min) | 35 | $5,940 | $170 |
| New patient visit (45+ min) | 44 | $4,807 | $109 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 110 | $2,830 | $12 |
See all 8 services
| Return visit (30+ min) | 80 | $14,134 | $94 |
| Long return visit (40+ min) | 41 | $10,067 | $140 |
| New patient visit (60+ min) | 35 | $5,940 | $170 |
| New patient visit (45+ min) | 44 | $4,807 | $109 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 110 | $2,830 | $12 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 13 | $1,093 | $26 |
| Hemoglobin a1c level | 43 | $666 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 54 | $465 | $3 |
Who their Medicare patients are
123 Original Medicare patients in 2024. Average age 70 · Women 71% · Also on Medicaid 49% · Health risk score 1.55. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 59% · Chronic kidney disease 45% · Coronary heart disease 25% · Depression 25% · COPD 16% · Atrial fibrillation 15% · Heart failure 13% · Stroke 11% · Cancer 10% · Dementia 9%.
The office billed $164,732, Medicare allowed $54,599 and paid $40,526; for 793 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 123 | 793 | 70 | 1.55 | $164,732 | $40,526 |
| 2023 | 53 | 142 | 71 | 1.38 | $47,850 | $12,712 |
| 2021 | 55 | 68 | 67 | 2.15 | $10,657 | $3,975 |
| 2020 | 38 | 99 | 68 | 2.96 | $21,876 | $7,972 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| New patient visit (45+ min) | 26 | $3,580 | $138 |
| New patient visit (60+ min) | 17 | $2,830 | $166 |
| Return visit (30+ min) | 19 | $2,338 | $106 |
| Long return visit (40+ min) | 12 | $2,230 | $149 |
| Blood glucose (sugar) test performed by hand-held instrument | 17 | $96 | $3 |
2021: 1 service
| Return visit (30+ min) | 34 | $2,325 | $68 |
2020: 2 services
| Hospital discharge day management, more than 30 minutes | 20 | $1,763 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,655 | $57 |
Medicaid work
$3,942 in 2024
Medicaid paid $3,942 for 66 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 54 | $3,061 |
| Long return visit (40+ min) | 12 | $881 |
| 2024 | 66 | 2 | 32 | $3,942 |
| 2021 | 33 | 1 | 18 | $922 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 33 | $922 |
Drugs they prescribed that Part D paid
$686,173
Pharmacies billed $686,173 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,484) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
474 generic and 901 brand-name prescriptions · $686,173 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 286 | $283,956 | $993 |
| Jardiance | 81 | $85,324 | $1,053 |
| Rybelsus | 41 | $55,185 | $1,346 |
| Mounjaro | 31 | $31,312 | $1,010 |
| Januvia | 24 | $24,660 | $1,027 |
See all 32 drugs
| Ozempic | 286 | $283,956 | $993 |
| Jardiance | 81 | $85,324 | $1,053 |
| Rybelsus | 41 | $55,185 | $1,346 |
| Mounjaro | 31 | $31,312 | $1,010 |
| Januvia | 24 | $24,660 | $1,027 |
| Synjardy | 14 | $17,574 | $1,255 |
| Farxiga | 12 | $17,243 | $1,437 |
| Synjardy Xr | 16 | $16,431 | $1,027 |
| Trulicity | 14 | $13,152 | $939 |
| Novolog Flexpen | 37 | $11,204 | $303 |
| Basaglar Kwikpen U-100 | 26 | $6,832 | $263 |
| Lantus Solostar | 74 | $6,521 | $88 |
| Humalog Kwikpen U-100 | 37 | $5,808 | $157 |
| Insulin Aspart Flexpen | 22 | $3,460 | $157 |
| Nano 2nd Gen Pen Needle | 53 | $3,365 | $63 |
| Humalog Mix 75-25 Kwikpen | 19 | $2,508 | $132 |
| Levothyroxine | 102 | $2,125 | $21 |
| Tirosint | 13 | $1,992 | $153 |
| Humulin N | 15 | $1,061 | $71 |
| Ultra-Fine Nano Pen Needle | 15 | $973 | $65 |
| Hydrocortisone | 19 | $721 | $38 |
| Lantus | 11 | $683 | $62 |
| Glipizide Er | 36 | $497 | $14 |
| Methimazole | 52 | $491 | $9 |
| Gabapentin | 32 | $450 | $14 |
| Atorvastatin | 30 | $402 | $13 |
| Metformin Hcl Er | 46 | $396 | $9 |
| Pioglitazone | 38 | $385 | $10 |
| Metformin | 43 | $379 | $9 |
| Alendronate | 16 | $176 | $11 |
| Glipizide | 12 | $147 | $12 |
| Amlodipine Besylate | 13 | $127 | $10 |
Year by year
| 2024 | 1,484 | 171 | 0% (0) | 61% | $686,173 |
| 2023 | 291 | 68 | 0% (0) | 56% | $122,470 |
| 2022 | 368 | 66 | 0% (0) | 53% | $109,860 |
| 2021 | 153 | 45 | 0% (0) | None | $35,593 |
| 2020 | 381 | 54 | None | None | $39,392 |
| 2019 | 416 | 49 | None | None | $60,527 |
| 2018 | 228 | 42 | None | None | $29,550 |
| 2017 | 71 | 16 | None | None | $10,759 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Ozempic | 21 | $24,750 | $1,179 |
| Jardiance | 15 | $13,269 | $885 |
| Toujeo Solostar | 14 | $8,151 | $582 |
| Humalog Kwikpen U-100 | 13 | $6,920 | $532 |
| Levothyroxine | 42 | $754 | $18 |
| Atorvastatin | 11 | $309 | $28 |
2022: 5 drugs
| Toujeo Max Solostar | 11 | $6,078 | $553 |
| Hydrocortisone | 49 | $1,483 | $30 |
| Levothyroxine | 52 | $754 | $15 |
| Alendronate | 20 | $118 | $6 |
| Euthyrox | 13 | $55 | $4 |
2021: 1 drug
| Levothyroxine | 15 | $263 | $18 |
2020: 8 drugs
| Atorvastatin | 32 | $400 | $13 |
| Losartan | 28 | $384 | $14 |
| Amlodipine Besylate | 36 | $273 | $8 |
| Carvedilol | 13 | $207 | $16 |
| Gabapentin | 15 | $205 | $14 |
| Metformin Hcl Er | 16 | $195 | $12 |
| Furosemide | 18 | $86 | $5 |
| Lisinopril | 13 | $69 | $5 |
2019: 12 drugs
| Humalog | 12 | $3,530 | $294 |
| Incruse Ellipta | 11 | $2,163 | $197 |
| Klor-Con | 11 | $1,994 | $181 |
| Atorvastatin | 17 | $421 | $25 |
| Carvedilol | 28 | $414 | $15 |
| Metformin Hcl Er | 20 | $247 | $12 |
| Losartan | 25 | $210 | $8 |
| Amlodipine Besylate | 30 | $184 | $6 |
| Omeprazole | 11 | $125 | $11 |
| Clopidogrel | 11 | $124 | $11 |
| Ranitidine | 11 | $109 | $10 |
| Lisinopril | 11 | $74 | $7 |
2018: 3 drugs
| Clopidogrel | 22 | $118 | $5 |
| Amlodipine Besylate | 14 | $71 | $5 |
| Lisinopril | 13 | $35 | $3 |
2017: 1 drug
| Clopidogrel | 12 | $63 | $5 |
Money from drug and device companies
$327 in 2025
| 2025 | 1 | 2 | None | $327 |
| 2023 | 6 | 7 | None | $235 |
| 2022 | 3 | 3 | None | $50 |
| 2021 | 1 | 1 | None | $25 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Intuitive Surgical | Da Vinci Surgical System | $327 | 2 payments
|
See all 2 published payments
| Intuitive Surgical | Travel · 2025-08-22 | Da Vinci Surgical System | $321 |
| Intuitive Surgical | Travel · 2025-08-19 | Da Vinci Surgical System | $6 |
See earlier years (2023, 2022, 2021)
2023: $235
| Dexcom | Dexcom G7 Gss (161) | $125 | 1 payment
|
| Lilly USA | Trulicity | $40 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $22 | 1 payment
|
| Insulet | Omnipod | $19 | 1 payment
|
| Averitas Pharma | Qutenza | $15 | 1 payment
|
| Lexicon Pharmaceuticals | Inpefa | $14 | 1 payment
|
2022: $50
| Abbott Laboratories | Freestyle Libre | $20 | 1 payment
|
| Lilly USA | Mounjaro | $16 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $14 | 1 payment
|
2021: $25
| Corcept Therapeutics | Korlym | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447771688
- Licence
- CA A188756California A188756: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 3400 Data Dr, Rancho Cordova, CA, 95670
- NPI first listed
- 2017-06-28
- NPI last updated
- 2023-09-08
- NPI record certified
- 2023-09-08
This is when the NPI record was last certified, not a medical board exam.